BRCA2 and lung adenocarcinoma: In conclusion, we report a refractory lung adenocarcinoma patient with extensive leptomeningeal metastases, harboring EGFR and somatic BRCA2 co-mutations, who exhibited a lasting response to Olaparib despite resistance to third-generation EGFR-TKIs.